AIM ImmunoTech Inc. (HXB)
Munich
Closed
Aug 24, 2026
Day's Range
4.4152 wk Range
4.41Overview - HXB - AIM ImmunoTech Inc.
Key Statistics
Valuation
Enterprise Value
1.91M
P/E (Trailing)
‪-0.51‬
PEG Ratio
‪0.0059‬
Price / Book
‪9.03‬
EV / EBITDA
‪-0.15‬
Profitability
Gross Margin
‪81.81%‬
Profit Margin
‪-45.45%‬
Operating Margin
‪-14,938.63%‬
Return on Assets
‪-241.40%‬
Return on Equity
‪142.67%‬
Ownership
Shares Outstanding
8.22M
Price stats
50-Day Avg
‪4.41‬
200-Day Avg
‪5.32‬
Peers - HXB - AIM ImmunoTech Inc.
Peer Comparison
Compared with companies in Biotechnology listed on Munich.
- HXBMunichAIM ImmunoTech Inc.-74.50%52-week change-0.51P/E (Trailing)‪-45.45%‬Profit Margin
- 0QFMunichModerna, Inc.+81.73%52-week change25.19P/E (Trailing)‪-141.42%‬Profit Margin
- 4E2MunichRelmada Therapeutics Inc.+86.82%52-week change-2.80P/E (Trailing)—Profit Margin
- 42ZMunichRevolution Medicines Inc.+82.82%52-week change-30.32P/E (Trailing)—Profit Margin
- 5JA1MunichSprint Bioscience AB+82.07%52-week change0.28P/E (Trailing)‪92.17%‬Profit Margin
- B9B9P0MunichNovabay Pharmaceuticals Inc. R+80.00%52-week change-0.01P/E (Trailing)—Profit Margin
- 87EMunichDianthus Therapeutics Inc.+78.62%52-week change-22.50P/E (Trailing)—Profit Margin
Profile Summary - HXB - AIM ImmunoTech Inc.
About
AIM ImmunoTech Inc. is a biopharmaceutical company specializing in immunology-focused drug development. The company concentrates on researching and developing therapeutics for multiple types of cancers, viral diseases, immune disorders, and immune-deficiency conditions, addressing areas where existing treatment…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
